文献速递艾滋病与性传播感染

DOLULAM 研究中多替拉韦加拉米夫定起始时 HIV-1 DNA 超深度测序分析

HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

DOLULAM 研究评估多替拉韦加拉米夫定双药治疗在经治 HIV-1 成人中维持病毒学抑制的疗效,第一年无病毒学失败。本病毒学子研究利用历史 DNA/RNA 基因型和基线 DNA 下一代测序(NGS)评估起始时 M184I/V 突变流行率。结果显示 27 例中 63% 存在 M184I/V,多数 M184V 见于历史 RNA 基因型,M184I 仅见于 DNA 基因型。

要点

  • 双药起始时 63%(17/27)患者存在 M184I/V 突变。
  • M184V 多见于历史 RNA 基因型,M184I 仅见于 DNA 基因型。
  • 10 例患者携带缺陷病毒基因组,均含 M184I 和终止密码子。

核心结论

  • 双药起始时高比例患者携带缺陷病毒基因组,M184I 为其标志。
  • 少数患者 PBMCs 中 M184V 仍为主要病毒变异。

研究设计与样本

  • DOLULAM 研究的病毒学子研究,纳入 27 例经治 HIV-1 成人。
  • 采用 Sanger 技术获取历史 DNA/RNA 基因型,Illumina 技术进行 HIV-1 DNA RT 和整合酶 NGS。

主要发现

  • DNA NGS 显示 45% 患者存在 RT minority resistant variants(MRV),21% 存在整合酶 MRV。
  • 结合所有基因型数据,27 例中 17 例(63%)观察到 M184I/V。
  • 多数 M184V 检测于历史 RNA 基因型(11 例中 8 例),M184I 仅检测于 DNA 基因型(10 例,其中 7 例为 MRV)。
  • 10 例患者显示细胞储库中缺陷病毒基因组,均包含 M184I 和终止密码子。
  • DOLULAM 起始时,DNA NGS 在 5 例患者中观察到 M184V,其中 1 例为 MRV。

临床怎么用

  • 在经治患者转换双药治疗前,可考虑 NGS 检测 DNA 基因型以识别 M184I/V 等少数变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The DOLULAM study assessed the efficacy of dolutegravir + lamivudine dual therapy to maintain virological suppression in heavily treatment-experienced HIV-1-infected adults. No virological failure occurred during the first year of the dual therapy. OBJECTIVES: A virological substudy was conducted to assess the prevalence of M184I/V mutations at dual therapy initiation using historical DNA/RNA genotypes and baseline DNA genotype obtained by next-generation sequencing (NGS). METHODS: HIV-1 RT sequences were obtained from DNA and/or historical RNA using Sanger technology. HIV-1 DNA RT and integrase NGS was performed using Illumina® technology. RESULTS: Among the 27 patients enrolled in the DOLULAM study, historical HIV DNA and RNA Sanger sequences were available in 14 and 18 patients, respectively. At the initiation of DOLULAM, DNA NGS genotypes showed that 45% and 21% of the patients harboured minority resistant variants (MRV) in RT and integrase, respectively. Combining all available genotype data, an M184I/V was observed in 17 of 27 (63%) of the patients. Most M184V were detected in historical RNA genotypes (n = 8 of 11), whereas M184I were exclusively detected in DNA genotypes (n = 10, including 7 as MRV). Ten patients displayed defective viral genomes in cellular reservoirs, all including M184I and stop codons. At the time of DOLULAM initiation, M184V was observed in DNA NGS in five patients, including one as MRV. CONCLUSIONS: These first NGS data on HIV DNA at initiation of a switch study showed (i) a high proportion of patients harbouring defective viral genomes, whose mutation M184I is a marker, and (ii) a low number of patients in whom M184V remained as a major viral variant in PBMCs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Charpentier C, Montes B, Perrier M, et al. HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study. J Antimicrob Chemother. 2017. PMID: 29091218. doi:10.1093/jac/dkx233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。